Ondine Biomedical appoints new Board of Directors
Retrieved on:
Tuesday, December 7, 2021
MSD, Merck, Solution, Public policy, Supervisory board, GLOBE, Medical Affairs Bureau, House, Audit committee, COO, CureVac, Reckitt, Board of directors, Eyeish, McCarthy, IPO, CEO, Medtech, RCGP, Therapy, ABPI, Partnership, McKesson Europe, EMEA, Board, Canadian House of Commons Page Program, Subclinical infection, Merck Sharp & Dohme Federal Credit Union, Microsoft Research, Entrepreneurship, NHS, NHS Confederation, Health Foundation, Pharmacia, The Advisory Board Company, Senior, Telefónica, Upjohn, Elanco, Partner, Legacy Fighting Alliance in 2018, CIPFA, Nose, Doctor of Philosophy, Merck & Co., Hospital, Silence Therapeutics, Acquisition, CFO, Commons, Management, Pharmaceutical industry
Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.
Key Points:
- Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.
- Carolyn Cross, Founder and CEO of Ondine, and Nicolas G. Loebel, PhD, President and Chief Technology Officer, will remain on the Board.
- Ondine is at the forefront of development of photodisinfection-based therapies to address the large and growing need for solutions to a broad spectrum infections, including drug-resistant strains.
- Steriwave has been deployed in Canadian hospitals for over ten years and has contributed to significant reductions in infection rates.